Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy

doi:10.3969/j.issn.1673-8640.2023.03.009

Abstract

Abstract: Objective To investigate the relationship between serum microRNA-326（miR-326） and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy. Methods Totally，50 patients with treatment-related hematological malignancy in the First Affiliated Hospital of Hebei North University from January 2012 to January 2021 were enrolled（study group），and 40 patients with hematological malignancy without primary solid tumors during the same period were enrolled as control group. Serum miR-326 levels were determined by real-time fluorescence quantitative polymerase chain reaction（RT-qPCR）. Study group received chemotherapy after admission，and they were classified into chemotherapy effective and chemotherapy ineffective groups according to the tumor assessment results. Serum miR-326 levels before and after chemotherapy were compared between the 2 groups，and the correlation between serum miR-326 levels and chemotherapy sensitivity in patients with treatment-related hematological malignancy was analyzed by Spearman correlation analysis. All the research subjects were followed up. The patients in study group were classified into survival and death groups according to the follow-up endpoint event（all-cause death），and the clinical data of the patients in the both groups were collected to analyze the factors influencing the prognosis of patients with treatment-related hematological malignancy using Logistic regression analysis. Receiver operating characteristic（ROC） curve was used to assess the effect of serum miR-326 on prognostic predictive value in patients with treatment-related hematological malignancy. Results Serum miR-326 level in study group was lower than that in control group（P<0.001）. Serum miR-326 levels were higher in chemotherapy effective group after chemotherapy compared with those before chemotherapy（P<0.05），and the difference between serum miR-326 levels before and after chemotherapy in chemotherapy ineffective group was not statistically significant（P>0.05）. Serum miR-326 levels were positively correlated with chemotherapy sensitivity in patients with treatment-related hematological malignancy（r=0.641，P<0.05）. The proportions of hypertension，infection，coagulation abnormalities，recurrent tumor chemotherapy cycles（≥5） and impairment of organ function were higher in death group than those in survival group，and serum miR-326 levels were lower than those in survival group（P<0.05）. Infection，coagulation abnormalities，impairment of organ function and low serum miR-326 levels were risk factors for poor prognosis in patients with treatment-related hematological malignancy（P<0.05）. The area under curve for serum miR-326 levels to predict the prognosis of patients with treatment-related hematological malignancy was 0.868，with the optimal cut-off value of 0.44，the sensitivity of 86.80% and the specificity of 78.10%. Conclusions Serum miR-326 shows abnormally low expression in patients with treatment-related hematological malignancy，which is related to chemotherapy sensitivity and is one of the relevant factors affecting patients' prognosis. It has a high predictive value for patients' prognosis.

Key words: MicroRNA-326, Treatment-related hematological malignancy, Chemotherapy, Sensitivity, Prognosis

CLC Number:

R393

CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy[J]. Laboratory Medicine, 2023, 38(3): 251-256.

Figures/Tables 5

References 16

[1]	HOU J Z, YE J C, PU J J, et al. Novel agents and regimens for hematological malignancies:recent updates from 2020 ASH annual meeting[J]. J Hematol Oncol, 2021, 14(1):66. DOI
[2]	OZDEMIR Z N, BOZDAG S C. Hematological malignancies and fertility[J]. Adv Exp Med Biol, 2020, 1288:103-115. DOI PMID
[3]	HUSSEN B M, HIDAYAT H J, SALIHI A, et al. MicroRNA:a signature for cancer progression[J]. Biomed Pharmacother, 2021, 138:111528. DOI URL
[4]	TANG Q, CHEN Z, ZHAO L, et al. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1[J]. Aging(Albany NY), 2019, 11(22):9982-9999.
[5]	ZHENG Y, GUO Z, LI Y. Long non-coding RNA prostate cancer-associated transcript 6 inhibited gefitinib sensitivity of non-small cell lung cancer by serving as a competing endogenous RNA of miR-326 to up-regulate interferon-alpha receptor 2[J]. Bioengineered, 2022, 13(2):3785-3796. DOI PMID
[6]	张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007.
[7]	把环环, 刘心. 恶性血液病并发第二肿瘤的临床特征与危险因素分析(附33例)[J]. 现代肿瘤医学, 2018, 26(16):2610-2614.
[8]	沈晶, 魏娜, 黄达永, 等. 治疗相关血液恶性肿瘤13例分析并文献复习[J]. 临床和实验医学杂志, 2018, 17(4):437-440.
[9]	KAWASHIRI T, KOBAYASHI D, UCHIDA M, et al. Analysis of secondary leukemia and myelodysplastic syndrome after chemotherapy for solid organ tumors using the Food and Drug Administration Adverse Event Reporting System(FAERS)[J]. J Pharm Pharm Sci, 2021, 24:499-508. DOI URL
[10]	JOLLES S, SMITH B D, VINH D C, et al. Risk factors for severe infections in secondary immunodeficiency:a retrospective US administrative claims study in patients with hematological malignancies[J]. Leuk Lymphoma, 2022, 63(1):64-73. DOI URL
[11]	SONG W, QIAN Y, ZHANG M H, et al. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(6):3049-3061.
[12]	WANG B, LI B, SI T. Knockdown of circ0082374 inhibits cell viability,migration,invasion and glycolysis in glioma cells by miR-326/SIRT1[J]. Brain Res, 2020, 1748:147108. DOI URL
[13]	DAMANTI C C, GAFFO E, LOVISA F, et al. MiR-26a-5p as a reference to normalize microRNA qRT-PCR levels in plasma exosomes of pediatric hematological malignancies[J]. Cells, 2021, 10(1):101. DOI URL
[14]	YIN S, DU W, WANG F, et al. MicroRNA-326 sensitizes human glioblastoma cells to curcumin via the SHH/GLI1 signaling pathway[J]. Cancer Biol Ther, 2018, 19(4):260-270. DOI PMID
[15]	GHODOUSI E S, ABERUYI N, RAHGOZAR S. Simultaneous changes in expression levels of BAALC and miR-326:a novel prognostic biomarker for childhood ALL[J]. Jpn J Clin Oncol, 2020, 50(6):671-678. DOI URL
[16]	ABERUYI N, RAHGOZAR S, GHODOUSI E S, et al. Drug resistance biomarkers and their clinical applications in childhood acute lymphoblastic leukemia[J]. Front Oncol, 2020, 9:1496. DOI URL

组别	例数	miR-326
组别	例数	化疗前	化疗后
化疗无效组	15	0.42±0.03	0.44±0.05
化疗有效组	35	0.41±0.04	0.74±0.08^*
t值		0.867	13.400
P值		0.390	<0.001

组别	例数	miR-326
组别	例数	化疗前	化疗后
化疗无效组	15	0.42±0.03	0.44±0.05
化疗有效组	35	0.41±0.04	0.74±0.08^*
t值		0.867	13.400
P值		0.390	<0.001

组别	例数	性别		年龄/岁	BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	高血脂/ [例（%）]	感染/ [例（%）]
组别	例数	男/ [例（%）]	女/ [例（%）]	年龄/岁	BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	高血脂/ [例（%）]	感染/ [例（%）]
存活组	28	19（67.86）	9（32.14）	49.05±9.86	22.34±2.12	12（42.86）	8（28.57）	9（32.14）	10（35.71）
死亡组	22	14（63.64）	8（36.36）	49.69±10.26	23.22±2.25	18（81.82）	6（27.27）	9（40.91）	17（77.27）
统计值		0.098		0.224	1.418	7.792	0.010	0.411	8.566
P值		0.754		0.824	0.163	0.005	0.919	0.522	0.003

组别	例数	性别		年龄/岁	BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	高血脂/ [例（%）]	感染/ [例（%）]
组别	例数	男/ [例（%）]	女/ [例（%）]	年龄/岁	BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	高血脂/ [例（%）]	感染/ [例（%）]
存活组	28	19（67.86）	9（32.14）	49.05±9.86	22.34±2.12	12（42.86）	8（28.57）	9（32.14）	10（35.71）
死亡组	22	14（63.64）	8（36.36）	49.69±10.26	23.22±2.25	18（81.82）	6（27.27）	9（40.91）	17（77.27）
统计值		0.098		0.224	1.418	7.792	0.010	0.411	8.566
P值		0.754		0.824	0.163	0.005	0.919	0.522	0.003

变量	变量	赋值说明
死亡	Y	1=是，0=否
高血压	X1	1=是，0=否
感染	X2	1=是，0=否
凝血功能异常	X3	1=是，0=否
再发肿瘤化疗周期（≥5个）	X4	1=是，0=否
脏器功能损伤	X5	1=是，0=否
miR-326	X6	连续变量